Teriparatide
PTH(1-34) · Bone-Building Anabolic Peptide
Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.
Overview
Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.
Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
FDA-approved for women with osteoporosis at high risk of fracture.
FDA-approved for men with primary or hypogonadal osteoporosis at high risk.
FDA-approved for men and women with osteoporosis from sustained corticosteroid use.
Research interest in accelerating fracture healing and bone repair.
Investigated for jawbone regeneration in dental applications.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Recombinant PTH fragment
- Chain length
- 34 residues
- Molecular weight
- 4118 Da
- Half-life
- ~1 h
- Typical dose
- 20mcg daily (FDA-approved dose)
- Frequency
- Once daily at same time each day
- Cycle length
- Maximum 2 years lifetime treatment
- Storage
- Pen: 2-8°C refrigerated, do not freeze. Discard after 28 days
Molecular data
- Type
- Recombinant PTH fragment
- Molecular weight
- 4118 Da
- Chain length
- 34 residues
- Half-life
- 60 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Osteoporosis treatment | SubQ (thigh or abdomen) | 20 mcg | Once daily |
Interactions
Antiresorptive agents often needed after teriparatide to maintain bone gains. Can be used sequentially.
Adequate calcium and vitamin D intake recommended during teriparatide therapy.
Different mechanisms; no known interactions.
Different mechanisms; no known interactions.
Quality checklist
- ✓Clear, colorless solution
- ✓Pharmaceutical grade (Forteo)
- ✓Proper cold chain maintained
- ✓Intact pen device
- !Research-grade products lack FDA oversight
- !Temperature excursions may affect potency
- ×Cloudy or discolored solution
- ×Particulates visible
- ×Exposed to freezing or high temperatures
What to expect
Safety
- Injection site reactions
- Nausea
- Headache
- Leg cramps
- Dizziness
- Joint pain
- Signs of hypercalcemia (confusion, fatigue, nausea)
- Persistent bone pain
- Allergic reactions
- Paget's disease of bone
- Prior skeletal radiation therapy
- History of skeletal malignancies
- Metabolic bone diseases other than osteoporosis
- Pre-existing hypercalcemia
- Pregnancy
FAQ
Why is teriparatide limited to 2 years when it builds bone so effectively?
Teriparatide is limited to 2 years due to a theoretical osteosarcoma risk observed in rat studies at very high doses over extended periods. Human clinical trials haven't shown this risk, but the FDA maintains the 2-year lifetime limit as a precautionary measure. After 2 years, antiresorptive therapy maintains the bone gains.
Can teriparatide reverse osteoporosis or just slow bone loss?
Teriparatide actively reverses osteoporosis by building new bone, unlike antiresorptive drugs that only slow loss. Clinical trials show 5-9% spine bone density increases and 65% fracture risk reduction - making it uniquely anabolic rather than protective.
Should teriparatide be taken with calcium and vitamin D?
Yes, adequate calcium and vitamin D intake are essential during teriparatide therapy. The peptide stimulates bone formation, which requires sufficient mineral substrate. Deficient calcium/vitamin D can blunt teriparatide's effects and potentially impair bone quality despite density gains.
How does teriparatide create an 'anabolic window' for bone formation?
Daily intermittent PTH exposure stimulates osteoblasts (bone-forming cells) more strongly than osteoclasts (bone-removing cells), creating a window where formation exceeds resorption. This contrasts with continuous PTH, which causes net bone loss. The daily injection timing is critical to maintain this anabolic advantage.